{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:12Z","timestamp":1793045472335,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02703-z","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:58:41Z","timestamp":1748307521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Patients with chronic hepatitis B exhibiting significant inflammation and fibrosis should pay particular attention to the status of hepatic steatosis during antiviral therapy"],"prefix":"10.1186","volume":"22","author":[{"given":"Bingqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenxue","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0269-1568","authenticated-orcid":false,"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/hep.32731","volume":"77","author":"D Loureiro","year":"2023","unstructured":"Loureiro D, Tout I, Narguet S, Bed CM, Roinard M, Sleiman A, et al. Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis. Hepatol Baltim Md. 2023;77:1348\u201365.","journal-title":"Hepatol Baltim Md"},{"key":"2703_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542\u201356.","journal-title":"J Hepatol"},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015;62:S47\u201364.","journal-title":"J Hepatol"},{"key":"2703_CR4","unstructured":"Lee M-H, Chen Y-T, Huang Y-H, Lu S-N, Yang T-H, Huang J-F et al. Chronic viral hepatitis B and C outweigh MASLD in the associated risk of cirrhosis and HCC. clin gastroenterol hepatol off clin pract. J Am Gastroenterol Assoc. 2024;S1542-3565(24)00198-8."},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"965548","DOI":"10.3389\/fimmu.2022.965548","volume":"13","author":"E Tourkochristou","year":"2022","unstructured":"Tourkochristou E, Assimakopoulos SF, Thomopoulos K, Marangos M, Triantos C. NAFLD and HBV interplay - related mechanisms underlying liver disease progression. Front Immunol. 2022;13:965548.","journal-title":"Front Immunol"},{"key":"2703_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"L-Y Mak","year":"2020","unstructured":"Mak L-Y, Hui RW-H, Fung J, Liu F, Wong DK-H, Cheung K-S, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73:800\u20136.","journal-title":"J Hepatol"},{"key":"2703_CR7","unstructured":"Non-alcoholic fatty. liver disease: A patient guideline - PubMed. [cited 2024 Apr 7]. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/34693236\/"},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/jvh.12766","volume":"25","author":"RWH Hui","year":"2018","unstructured":"Hui RWH, Seto W-K, Cheung K-S, Mak L-Y, Liu KSH, Fung J, et al. Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case-control study. J Viral Hepat. 2018;25:97\u2013104.","journal-title":"J Viral Hepat"},{"key":"2703_CR9","doi-asserted-by":"publisher","first-page":"100350","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep Innov Hepatol. 2021;3:100350.","journal-title":"JHEP Rep Innov Hepatol"},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1111\/jgh.13536","volume":"32","author":"AWH Chan","year":"2017","unstructured":"Chan AWH, Wong GLH, Chan H-Y, Tong JHM, Yu Y-H, Choi PCL, et al. Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 2017;32:667\u201376.","journal-title":"J Gastroenterol Hepatol"},{"key":"2703_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, et al. Nonalcoholic steatohepatitis is associated with Liver-Related outcomes and All-Cause mortality in chronic hepatitis B. Hepatol Baltim Md. 2020;71:539\u201348.","journal-title":"Hepatol Baltim Md"},{"key":"2703_CR12","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"P Lampertico","year":"2017","unstructured":"Lampertico P, Agarwal K, Berg T, Buti M, Janssen HLA, Papatheodoridis G, et al. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370\u201398.","journal-title":"J Hepatol"},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4:883\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1111\/apt.16067","volume":"52","author":"MJ Sonneveld","year":"2020","unstructured":"Sonneveld MJ, Brouwer WP, Hansen BE, Chan HL-Y, Piratvisuth T, Jia J-D, et al. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis. Aliment Pharmacol Ther. 2020;52:1399\u2013406.","journal-title":"Aliment Pharmacol Ther"},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"e28501","DOI":"10.1002\/jmv.28501","volume":"95","author":"Y Tang","year":"2023","unstructured":"Tang Y, Fan R, Lan Z, Xie Q, Zhang J, Liang X, et al. Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B. J Med Virol. 2023;95:e28501.","journal-title":"J Med Virol"},{"key":"2703_CR16","doi-asserted-by":"publisher","first-page":"e29156","DOI":"10.1002\/jmv.29156","volume":"95","author":"M Zhang","year":"2023","unstructured":"Zhang M, Chen S, Wu X, Zhou J, Wang T, Liu H, et al. Persistent steatosis correlates with decreased fibrosis regression during anti-HBV treatment in patients with chronic HBV infection. J Med Virol. 2023;95:e29156.","journal-title":"J Med Virol"},{"key":"2703_CR17","doi-asserted-by":"publisher","first-page":"100322","DOI":"10.1016\/j.jhepr.2021.100322","volume":"3","author":"SM Francque","year":"2021","unstructured":"Francque SM, Marchesini G, Kautz A, Walmsley M, Dorner R, Lazarus JV, et al. Non-alcoholic fatty liver disease: A patient guideline. JHEP Rep. 2021;3:100322.","journal-title":"JHEP Rep"},{"key":"2703_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol. 1991;13:372\u20134.","journal-title":"J Hepatol"},{"key":"2703_CR19","first-page":"127","volume":"21","author":"Chinese Society of Hepatology, Chinese Medical Association","year":"2020","unstructured":"Chinese Society of Hepatology, Chinese Medical Association. Chinese society of gastroenterology, Chinese medical association; Chinese society of infectious diseases, Chinese medical association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis. 2020;21:127\u201338.","journal-title":"J Dig Dis"},{"key":"2703_CR20","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.2337\/dc24-S002","volume":"47","author":"NA ElSayed","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, Aleppo G, Bannuru RR, Bruemmer D, Collins BS, et al. 2. Diagnosis and classification of diabetes: Standards of care in Diabetes\u20142024. Diabetes Care. 2024;47:S20\u201342.","journal-title":"Diabetes Care"},{"key":"2703_CR21","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912\u20134018.","journal-title":"Eur Heart J"},{"key":"2703_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161365.GL","volume":"22","author":"WT Garvey","year":"2016","unstructured":"Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22:1\u2013203.","journal-title":"Endocr Pract"},{"key":"2703_CR23","first-page":"000","volume":"000","author":"M Rugivarodom","year":"2022","unstructured":"Rugivarodom M, Pongpaibul A, Chainuvati S, Nimanong S, Chotiyaputta W, Tanwandee T, et al. Prognostic relevance of metabolic Dysfunction-associated steatohepatitis for patients with chronic hepatitis B. J Clin Transl Hepatol. 2022;000:000\u2013000.","journal-title":"J Clin Transl Hepatol"},{"key":"2703_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1186\/s12879-023-08632-y","volume":"23","author":"Y-N Dai","year":"2023","unstructured":"Dai Y-N, Xu C-F, Pan H-Y, Chen M-J, Yu C-H. Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection. BMC Infect Dis. 2023;23:637.","journal-title":"BMC Infect Dis"},{"key":"2703_CR25","first-page":"575","volume":"16","author":"W-K Seto","year":"2018","unstructured":"Seto W-K, Hui RWH, Mak L-Y, Fung J, Cheung K-S, Liu KSH, et al. Association between hepatic steatosis, measured by controlled Attenuation parameter, and fibrosis burden in chronic hepatitis B. clin gastroenterol hepatol off clin pract. J Am Gastroenterol Assoc. 2018;16:575\u2013e5832.","journal-title":"J Am Gastroenterol Assoc"},{"key":"2703_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1478-3231.2011.02453.x","volume":"31","author":"S Petta","year":"2011","unstructured":"Petta S, Camm\u00e0 C, Di Marco V, Macaluso FS, Maida M, Pizzolanti G, et al. Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. Liver Int Off J Int Assoc Study Liver. 2011;31:507\u201315.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2703_CR27","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1002\/hep.29009","volume":"65","author":"Y Sun","year":"2017","unstructured":"Sun Y, Zhou J, Wang L, Wu X, Chen Y, Piao H, et al. New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment. Hepatology. 2017;65:1438\u201350.","journal-title":"Hepatology"},{"key":"2703_CR28","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/liv.13271","volume":"37","author":"P Charatcharoenwitthaya","year":"2017","unstructured":"Charatcharoenwitthaya P, Pongpaibul A, Kaosombatwattana U, Bhanthumkomol P, Bandidniyamanon W, Pausawasdi N, et al. The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response. Liver Int. 2017;37:542\u201351.","journal-title":"Liver Int"},{"key":"2703_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/cld.728","volume":"12","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang K, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Clin Liver Dis. 2018;12:33\u20134.","journal-title":"Clin Liver Dis"},{"key":"2703_CR30","unstructured":"Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization. 2015 [cited 2024 Apr 10]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK305553\/"},{"key":"2703_CR31","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jhep.2021.05.003","volume":"75","author":"Y Nan","year":"2021","unstructured":"Nan Y, An J, Bao J, Chen H, Chen Y, Ding H, et al. The Chinese society of hepatology position statement on the redefinition of fatty liver disease. J Hepatol. 2021;75:454\u201361.","journal-title":"J Hepatol"},{"key":"2703_CR32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10620-012-2441-8","volume":"58","author":"J Fung","year":"2013","unstructured":"Fung J, Yuen M-F, Lai C-L. The role of steatosis in HBsAg seroclearance for patients with chronic hepatitis B infection: fact or fiction? Dig Dis Sci. 2013;58:20\u20132.","journal-title":"Dig Dis Sci"},{"key":"2703_CR33","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1093\/infdis\/jiaa739","volume":"224","author":"J Li","year":"2021","unstructured":"Li J, Yang H-I, Yeh M-L, Le MH, Le AK, Yeo YH, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B. J Infect Dis. 2021;224:294\u2013302.","journal-title":"J Infect Dis"},{"key":"2703_CR34","first-page":"1052","volume":"40","author":"J Li","year":"2020","unstructured":"Li J, Le AK, Chaung KT, Henry L, Hoang JK, Cheung R, et al. Fatty liver is not independently associated with the rates of complete response to oral antiviral therapy in chronic hepatitis B patients. Liver Int Off J Int Assoc Study Liver. 2020;40:1052\u201361.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2703_CR35","first-page":"713","volume":"36","author":"Y Fukuda","year":"2016","unstructured":"Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, et al. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int Off J Int Assoc Study Liver. 2016;36:713\u201320.","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"2703_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12944-019-0986-7","volume":"18","author":"N Fan","year":"2019","unstructured":"Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis. 2019;18:39.","journal-title":"Lipids Health Dis"},{"key":"2703_CR37","doi-asserted-by":"crossref","unstructured":"Haase CL, Lopes S, Olsen AH, Satylganova A, Schnecke V, McEwan P. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database. Int J Obes. 2005. 2021;45:1249\u201358.","DOI":"10.1038\/s41366-021-00788-4"},{"key":"2703_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u201378. e5 quiz e14-15.","journal-title":"Gastroenterology"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02703-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02703-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T13:03:03Z","timestamp":1748350983000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02703-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02703-z","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards set forth in the Helsinki Declaration and its subsequent amendments and was approved by the Institutional Review Board of Beijing Ditan Hospital, Capital Medical University (NO.DTEC-KY2021-046-04). This is a retrospective study involving no diagnostic or therapeutic interventions, and the data were anonymized. Therefore, the research centre\u2019s ethics committee waived the requirement for patient informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"During the preparation of this work the author(s) used ChatGPT 4.0 in order to improve readability and language. After using this tool, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies in the writing process"}}],"article-number":"164"}}